LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Genotype-phenotype correlations in Charcot-Marie-Tooth disease type 2 caused by mitofusin 2 mutations.

    Calvo, Judith / Funalot, Benoît / Ouvrier, Robert A / Lazaro, Leila / Toutain, Annick / De Mas, Philippe / Bouche, Pierre / Gilbert-Dussardier, Brigitte / Arne-Bes, Marie-Christine / Carrière, Jean-Pierre / Journel, Hubert / Minot-Myhie, Marie-Christine / Guillou, Claire / Ghorab, Karima / Magy, Laurent / Sturtz, Franck / Vallat, Jean-Michel / Magdelaine, Corinne

    Archives of neurology

    2009  Volume 66, Issue 12, Page(s) 1511–1516

    Abstract: Background: Mutations in the gene encoding mitofusin 2 (MFN2) cause Charcot-Marie-Tooth disease type 2 (CMT2), with heterogeneity concerning severity and associated clinical features.: Objective: To describe MFN2 mutations and associated phenotypes ... ...

    Abstract Background: Mutations in the gene encoding mitofusin 2 (MFN2) cause Charcot-Marie-Tooth disease type 2 (CMT2), with heterogeneity concerning severity and associated clinical features.
    Objective: To describe MFN2 mutations and associated phenotypes in patients with hereditary motor and sensory neuropathy (HMSN).
    Design: Direct sequencing of the MFN2 gene and clinical investigations of patients with MFN2 mutations.
    Setting: Molecular genetics laboratory of a university hospital and the Limoges National Referral Center for Rare Peripheral Neuropathies.
    Patients: One hundred fifty index patients with HMSN and a median motor nerve conduction velocity of 25 m/s or greater and without mutations in the genes encoding connexin 32 and myelin protein zero.
    Main outcome measures: Results of genetic analyses and phenotypic observations.
    Results: Twenty different missense mutations were identified in 20 index patients. Mutation frequency was 19 of 107 (17.8%) in patients with CMT2 and 1 of 43 (2.3%) in patients with a median motor nerve conduction velocity less than 38 m/s. Four patients had proven de novo mutations, 8 families had autosomal dominant inheritance, and 3 had autosomal recessive inheritance. The remaining 5 patients were sporadic cases with heterozygous mutations. Phenotypes varied from mild forms to early-onset severe forms. Additional features were encountered in 8 patients (32%). Six patients underwent sural nerve biopsy: electronic microscopy showed prominent mitochondrial abnormalities on longitudinal sections.
    Conclusions: MFN2 mutations are a frequent cause of CMT2, with variable severity and either dominant or recessive inheritance. MFN2 gene testing must be a first-line analysis in axonal HMSN irrespective of the mode of inheritance or the severity of the peripheral neuropathy.
    MeSH term(s) Adolescent ; Adult ; Aged ; Charcot-Marie-Tooth Disease/classification ; Charcot-Marie-Tooth Disease/genetics ; Charcot-Marie-Tooth Disease/pathology ; Child ; Child, Preschool ; Female ; GTP Phosphohydrolases ; Genes, Dominant ; Genes, Recessive ; Genetic Markers/genetics ; Genotype ; Humans ; Male ; Membrane Proteins/genetics ; Middle Aged ; Mitochondrial Proteins/genetics ; Mutation, Missense/genetics ; Phenotype ; Severity of Illness Index ; Young Adult
    Chemical Substances Genetic Markers ; Membrane Proteins ; Mitochondrial Proteins ; GTP Phosphohydrolases (EC 3.6.1.-) ; MFN2 protein, human (EC 3.6.1.-)
    Language English
    Publishing date 2009-12
    Publishing country United States
    Document type Comparative Study ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80049-1
    ISSN 1538-3687 ; 0003-9942
    ISSN (online) 1538-3687
    ISSN 0003-9942
    DOI 10.1001/archneurol.2009.284
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article: A liquid hexavalent combined vaccine against diphtheria, tetanus, pertussis, poliomyelitis, Haemophilus influenzae type B and hepatitis B: review of immunogenicity and safety.

    Mallet, Eric / Belohradsky, Bernd H / Lagos, Rosanna / Gothefors, Leif / Camier, Patrice / Carrière, Jean-Pierre / Kanra, Güler / Hoffenbach, Agnès / Langue, Jacques / Undreiner, François / Roussel, François / Reinert, Philippe / Flodmark, Carl-Erik / Stojanov, Silvia / Liese, Johannes / Levine, Myron M / Muñoz, Alma / Schödel, Florian / Hessel, Luc

    Vaccine

    2004  Volume 22, Issue 11-12, Page(s) 1343–1357

    Abstract: To reduce the number of injections needed to comply with paediatric vaccination requirements, a liquid, hexavalent vaccine (DTaP-IPV-PRP-T-HBs; Hexavac; Aventis Pasteur MSD) has been developed for primary and booster vaccination of infants and toddlers. ... ...

    Abstract To reduce the number of injections needed to comply with paediatric vaccination requirements, a liquid, hexavalent vaccine (DTaP-IPV-PRP-T-HBs; Hexavac; Aventis Pasteur MSD) has been developed for primary and booster vaccination of infants and toddlers. In extensive clinical studies, Hexavac has been shown to be highly immunogenic. Seroconversion or seroprotective titres of antibodies against all antigens were achieved in the majority of infants following a primary series of three doses administered at 1-2-month intervals from 2 months of age. Hexavac also induced immunologic memory, as evidenced by the anamnestic response to booster vaccination at 12-18 months of age. These responses were comparable with those seen following concomitant administration of Pentavac (DTaP-IPV//PRP-T) and monovalent hepatitis B vaccine (H-B-Vax II), and were also within the ranges observed for other relevant licensed vaccines. Clinical studies comparing the immunogenicity of Hexavac administered at either 2, 3 and 4 months or 2, 4 and 6 months demonstrated that it can be used by either vaccination schedule. A further study also supported the use of primary doses of Hexavac at 3 and 5 months with a booster at 12 months of age. Hexavac demonstrated a good reactogenicity and tolerability profile. The most frequently reported adverse events after both primary and booster doses were local reactions of redness and swelling/induration and a systemic response of mild fever, irrespective of the vaccine used for priming. Hexavac provided immunity against six important childhood diseases with a single injection at each visit.
    MeSH term(s) Diphtheria-Tetanus-Pertussis Vaccine/adverse effects ; Diphtheria-Tetanus-Pertussis Vaccine/immunology ; Female ; Haemophilus Vaccines/adverse effects ; Haemophilus Vaccines/immunology ; Haemophilus influenzae type b/immunology ; Hepatitis B Vaccines/adverse effects ; Hepatitis B Vaccines/immunology ; Humans ; Immunization, Secondary ; Infant ; Male ; Poliovirus Vaccines/adverse effects ; Poliovirus Vaccines/immunology ; Vaccines, Combined/adverse effects ; Vaccines, Combined/immunology
    Chemical Substances Diphtheria-Tetanus-Pertussis Vaccine ; Haemophilus Vaccines ; Hepatitis B Vaccines ; Poliovirus Vaccines ; Vaccines, Combined
    Language English
    Publishing date 2004-03-29
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 605674-x
    ISSN 1873-2518 ; 0264-410X
    ISSN (online) 1873-2518
    ISSN 0264-410X
    DOI 10.1016/j.vaccine.2003.09.039
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top